| Pharmaceutical Information |
| Drug Name |
Nefazodone hydrochloride |
| Drug ID |
BADD_D01547 |
| Description |
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. |
| Indications and Usage |
For the treatment of depression. |
| Marketing Status |
approved; withdrawn |
| ATC Code |
N06AX06 |
| DrugBank ID |
DB01149
|
| KEGG ID |
D00819
|
| MeSH ID |
C051752
|
| PubChem ID |
54911
|
| TTD Drug ID |
D0X7DE
|
| NDC Product Code |
0093-1025; 0093-1026; 63629-7046; 63415-0015; 0093-1024; 0093-7113; 0093-7178 |
| UNII |
27X63J94GR
|
| Synonyms |
nefazodone | Serzone | Dutonin | Nefadar | nefazodone hydrochloride | Lin-Nefazodone | Menfazona | Rulivan | Apo-Nefazodone |
|
| Chemical Information |
| Molecular Formula |
C25H33Cl2N5O2 |
| CAS Registry Number |
82752-99-6 |
| SMILES |
CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
